ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% — Competitive Intelligence Brief

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% (ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aryl hydrocarbon receptor (AhR) agonist. Area: Dermatology.

phase 3 Aryl hydrocarbon receptor (AhR) agonist AhR (Aryl hydrocarbon receptor) Dermatology Small molecule

Target snapshot

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% (ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%) — Arcutis Biotherapeutics, Inc.. ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% TARGET	ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Arcutis Biotherapeutics, Inc.	phase 3	Aryl hydrocarbon receptor (AhR) agonist	AhR (Aryl hydrocarbon receptor)
VTAMA (tapinarof) cream, 1%	VTAMA (tapinarof) cream, 1%	Organon and Co	marketed	Aryl hydrocarbon receptor (AhR) agonist	Aryl hydrocarbon receptor (AhR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aryl hydrocarbon receptor (AhR) agonist class)

1. Arcutis Biotherapeutics, Inc. · 1 drug in this class
2. Organon and Co · 1 drug in this class